In this conversation, Speaker A introduces the concept of Longevity Escape Velocity (LEV), arguing that early‑generation therapies will only repair a subset of biological damage—what they call "easy" damage—while leaving more stubborn "difficult" damage untouched. Even if the easy damage is repaired frequently, the accumulation of difficult damage will eventually cause disease and death. The LEV hypothesis posits that if a first‑generation treatment portfolio can add roughly 20 years of healthy life, that window gives researchers time to develop interventions that convert difficult damage into easy‑to‑repair forms. When those new therapies become available two decades later, a second round of rejuvenation could grant another 20 years, and so on. This iterative cycle leads to the optimistic conclusion that achieving human longevity escape velocity may be possible in the near future.
